Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Total Liabilities (2016 - 2025)

Historic Total Liabilities for Neurocrine Biosciences (NBIX) over the last 15 years, with Q4 2025 value amounting to $1.4 billion.

  • Neurocrine Biosciences' Total Liabilities rose 2209.03% to $1.4 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $1.4 billion, marking a year-over-year increase of 2209.03%. This contributed to the annual value of $1.4 billion for FY2025, which is 2209.03% up from last year.
  • As of Q4 2025, Neurocrine Biosciences' Total Liabilities stood at $1.4 billion, which was up 2209.03% from $1.3 billion recorded in Q3 2025.
  • In the past 5 years, Neurocrine Biosciences' Total Liabilities registered a high of $1.4 billion during Q4 2025, and its lowest value of $640.8 million during Q1 2021.
  • Moreover, its 4-year median value for Total Liabilities was $846.1 million (2023), whereas its average is $940.4 million.
  • Its Total Liabilities has fluctuated over the past 5 years, first plummeted by 386.65% in 2021, then skyrocketed by 6086.18% in 2024.
  • Over the past 4 years, Neurocrine Biosciences' Total Liabilities (Quarter) stood at $671.3 million in 2021, then skyrocketed by 51.85% to $1.0 billion in 2023, then rose by 10.75% to $1.1 billion in 2024, then grew by 22.09% to $1.4 billion in 2025.
  • Its Total Liabilities was $1.4 billion in Q4 2025, compared to $1.3 billion in Q3 2025 and $1.2 billion in Q2 2025.